Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Janssen-Cilag International N.V
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 5 ans
This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients with moderate to severe psoriasis
The primary objectives of this study are to evaluate the efficacy and safety of 2 SC dosing tiers of ustekinumab in the treatment of dolescent subjects 12 to 18 years of age with moderate to severe c...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 5 ans
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients with Schizophrenia
To demonstrate, in patients stabilized on the paliperidone palmitate 1 month formulation (PP1M), that paliperidone palmitate 3 month formulation (PP3M) is not less effective than PP1M in the treatment...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 5 ans
A study of the safety and efficacy of CNTO328 in combination with best supportive care compared to best supportive care in patients with Multicentric Castleman's Disease
The primary objective of this study is to demonstrate that CNTO 328 in combination with BSC is superior to BSC in terms of durable tumor and symptomatic response among subjects with multicentric Castl...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 5 ans
A study to investigate the efficacy of sirukumab in addition to the current antidepressant treatment in adults with depression Badanie w celu oceny skuteczności sirukumabu jako leku wspomagającego stosowanego w skojarzeniu z terapią przeciwdepresyjną u dorosłych pacjentów z dużą depresją
To evaluate the efficacy of sirukumab as adjunctive treatment to antidepressant therapy (monoaminergic antidepressant) where sirukumab (administered as a 50mg subcutaneous (SC) injection at Day 1, Day...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 5 ans
A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy
The primary objective is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of RA and inhibition of radiographic progression in subjects with active RA who are ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 5 ans
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(alpha) Naive Participants With Active Radiographic Axial Spondyloarthritis Klinické hodnocení vyhodnocující účinnost a bezpečnost ustekinumabu v léčbě anti-TNFα naivních subjektů s aktivní radiografickou axiální spondyloartritidou
The purpose of this study is to assess the efficacy of ustekinumab, in adult participants with active radiographic axial spondyloarthritis (AxSpA), who are naive to anti-TNF alpha agents, as measured ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 5 ans
A Non-Randomized, Within Subject Placebo-Controlled Exploratory Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal EEG Response in Subjects with Photosensitive Epilepsy
To determine oral doses of JNJ-26489112 that result in complete suppression or reduction of IPS induced photoparoxysmal-EEG response, a marker of antiepileptic activity. To assess the safety, tolerab...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 5 ans
Open-Label Study to Evaluate the Safety and Pharmacokinetics of Single-and Multiple-Dose Extended-Release OROS Paliperidone in Pediatric Subjects (>/= 10 to </= 17 Years of Age) with Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
To characterize the pharmacokinetics of paliperidone after single-dose administration and at steady state following multiple oral administrations of paliperidone ER (using population PK modeling), in ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 5 ans
A Study of Guselkumab in the Treatment of Participants with Moderate to Severe Plaque-Type Psoriasis
• To evaluate the efficacy of guselkumab in the treatment of subjects with moderate to severe plaque-type psoriasis. • To assess the safety and tolerability of guselkumab in subjects with moderate to...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 5 ans
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants with Smoldering Multiple Myeloma
- To evaluate if daratumumab can effectively decrease M protein in subjects with intermediate or high-risk SMM as assessed by CR rate - To determine if daratumumab reduces the progression/death rate ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
3
4
5
6
7
8
9
10
Suivant